Skip to main content
Premium Trial:

Request an Annual Quote

Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich

NEW YORK (GenomeWeb) – The Broad Institute has granted GE Healthcare and Sigma-Aldrich non-exclusive licenses to intellectual property covering CRISPR/Cas9 for research applications, the companies announced separately today.

Under the arrangements, both companies will have access to the CRISPR IP portfolio, which includes patents related to the use of the gene-editing technology in eukaryotic cells that was pioneered in the lab of Broad researcher Feng Zhang.

According to GE Healthcare, the Broad license will allow it to expand its recently launched Dharmacon Edit-R CRISPR/Cas9 gene-engineering system for creating permanent and heritable gene knockouts in cells.

Sigma-Aldrich, meantime, stated that with the license, it will be able to create pre-designed or customizable individual lentiviral CRISPR clones and off-the-shelf or custom lentiviral CRISPR pools. The firm also noted that it already serves as the exclusive distributor for Broad's Mission shRNA and ORF libraries.

Specific terms of the licensing deals were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.